

<https://doi.org/10.46344/JBINO.2025.v14i04.03>

ANTIRETROVIRAL THERAPY AND SICKLE CELL DISEASE: BALANCING EFFICACY AND TOXICITY

Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Email : emmanuelobeagu@yahoo.com,

ABSTRACT

The management of HIV in patients with sickle cell disease (SCD) presents unique challenges, as both conditions require careful treatment strategies to address their distinct pathophysiologies. Antiretroviral therapy (ART) plays a critical role in controlling HIV, but its effects on SCD patients must be carefully balanced to avoid exacerbating hematologic and organ-related complications. This review explores the efficacy and potential toxicities of ART in the context of SCD, highlighting the importance of optimizing treatment regimens while minimizing adverse effects. We discuss the complex interplay between ART and SCD, focusing on challenges related to drug interactions, toxicity, and the impact on key organs such as the kidneys, liver, and bone marrow. SCD patients receiving ART are at risk for hematologic complications, including bone marrow suppression, which can worsen the anemia characteristic of SCD and complicate pain crises. Renal toxicity, particularly from certain ART drugs like tenofovir, further compounds the risk of kidney-related complications already prevalent in SCD patients. Additionally, ART-induced gastrointestinal and hepatic toxicity can interfere with the management of SCD-related complications, affecting the patient's overall health. Therefore, careful monitoring of kidney, liver, and hematologic function is essential for managing co-infected patients.

Keywords: *Antiretroviral Therapy, Sickle Cell Disease, Drug Toxicity, Treatment Efficacy, Co-infection Management*

Introduction

Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin, leading to the deformation of red blood cells into a sickle shape. These sickled cells cause blockages in blood vessels, resulting in episodes of acute pain, organ damage, and a range of long-term health complications. People with SCD face multiple challenges related to hemolysis, pain crises, anemia, and organ damage, particularly to the kidneys, liver, and lungs. The management of SCD has advanced significantly, but it remains a complex and lifelong condition, requiring continuous monitoring and intervention. In recent decades, the global HIV epidemic has added an additional layer of complexity for individuals with SCD, particularly in areas with high rates of both diseases.¹⁻² Human immunodeficiency virus (HIV) is a viral infection that primarily targets and weakens the immune system, rendering individuals more vulnerable to infections, cancers, and other illnesses. The introduction of antiretroviral therapy (ART) has revolutionized the management of HIV, significantly improving the prognosis for individuals living with the virus. However, when HIV coexists with other chronic conditions, such as SCD, managing the intersection of these diseases becomes highly challenging. ART, while effective in suppressing HIV replication, can have adverse effects on patients with SCD due to drug interactions, organ toxicity, and hematologic complications. This creates the need for a careful balancing act between controlling HIV and minimizing the toxicity that may exacerbate SCD-related complications.³⁻⁴ The management of HIV in patients with SCD presents a particularly complicated scenario. ART regimens must be chosen carefully to ensure that the drugs used to suppress HIV do not trigger or exacerbate SCD-related

complications, such as renal failure, liver toxicity, or bone marrow suppression. Furthermore, some antiretroviral drugs, such as those in the nucleoside reverse transcriptase inhibitors (NRTIs) class, can cause kidney damage, while certain protease inhibitors and integrase inhibitors can interact with the liver's detoxification system, leading to hepatotoxicity. These potential toxicities necessitate regular monitoring and modifications to treatment regimens to address the individual needs of SCD patients with HIV.⁵⁻⁶

The interaction between HIV and SCD extends beyond just medication. Both diseases independently and synergistically impact various organ systems. The immune system in SCD patients is already compromised due to chronic inflammation and recurrent pain episodes, while the immune suppression caused by HIV further increases vulnerability to infections, complications, and poor outcomes. Additionally, the compromised vascular system in SCD patients can be further aggravated by the immunologic disturbances induced by HIV, making the management of these coexisting conditions particularly difficult. The co-occurrence of these two conditions increases the likelihood of cardiovascular, renal, and hepatic dysfunction, necessitating a comprehensive approach to management.⁷⁻⁸ In addition to physical health challenges, the intersection of HIV and SCD also introduces psychosocial difficulties. Patients with both HIV and SCD may face stigma related to their HIV diagnosis, compounded by the long-term nature of SCD care. These challenges can impact treatment adherence and overall well-being. The social and emotional burden of managing two chronic conditions can lead to depression, anxiety, and a lack of engagement with healthcare providers, further complicating the management of both diseases. A

multidisciplinary approach that integrates psychological support alongside physical care is vital in ensuring that patients are equipped to handle both the clinical and emotional toll of living with HIV and SCD.⁹⁻¹⁰ Given these complexities, healthcare providers must adopt a highly personalized approach to managing HIV in SCD patients. Regular monitoring of kidney function, liver enzymes, bone marrow, and viral load is essential to ensure that ART is both effective and non-toxic. The selection of ART drugs should account for potential drug-drug interactions, while also considering the individual's baseline organ function and any co-existing health issues. Collaboration among specialists, including hematologists, infectious disease experts, nephrologists, and pharmacists, is crucial to providing comprehensive care that addresses the multifaceted needs of these patients.¹¹⁻¹²

Antiretroviral Therapy Efficacy in Sickle Cell Disease

Antiretroviral therapy (ART) is the cornerstone of treatment for individuals living with HIV, effectively reducing viral load, improving immune function, and enhancing quality of life. However, the use of ART in patients with comorbid sickle cell disease (SCD) presents distinct challenges due to the interplay between the two conditions. While ART has been shown to control HIV replication and prevent disease progression, its efficacy in the context of SCD requires a nuanced understanding of how ART interacts with the pathophysiology of SCD.¹³⁻¹⁴ In patients with HIV and SCD, ART's primary goal is to suppress the viral load to undetectable levels, thereby reducing the risk of opportunistic infections and enhancing immune function. Several studies have demonstrated that ART is effective in managing HIV in individuals with SCD, with most patients achieving viral suppression and maintaining immune function within

acceptable ranges. The most commonly used ART regimens, consisting of a combination of nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs), have been proven to be effective in managing viral loads in this population. These treatments not only reduce HIV-associated morbidity and mortality but also improve the quality of life for individuals living with HIV and SCD.¹⁵⁻¹⁶ Despite the overall effectiveness of ART in controlling HIV, the simultaneous management of SCD and HIV is complicated by the potential toxicities of antiretroviral drugs. Many ART drugs can exacerbate SCD-related complications, such as renal toxicity, bone marrow suppression, and hepatic dysfunction. For instance, NRTIs like tenofovir and zidovudine are associated with renal impairment, which can worsen the kidney complications already present in some SCD patients. Additionally, certain protease inhibitors can increase the risk of bone marrow suppression, which may aggravate anemia and increase the frequency of pain crises in individuals with SCD. Therefore, while ART is effective in managing HIV, its use in SCD patients requires careful selection and monitoring to avoid further complicating their disease.¹⁷⁻¹⁸ Furthermore, the efficacy of ART in patients with SCD may be influenced by pharmacokinetic interactions between ART drugs and the drugs used to manage SCD. For example, drugs like hydroxyurea, commonly used to reduce pain crises and improve hemoglobin levels in SCD patients, may interact with certain ART medications, potentially altering their effectiveness or increasing the risk of adverse effects. Consequently, healthcare providers must closely monitor drug-drug interactions and adjust treatment regimens as necessary to

ensure the efficacy of both HIV and SCD therapies.¹⁹⁻²⁰

Toxicities of Antiretroviral Therapy in Sickle Cell Disease

While antiretroviral therapy (ART) has significantly improved the prognosis of individuals living with HIV, the co-existence of sickle cell disease (SCD) introduces additional challenges. SCD is a genetic blood disorder that impacts multiple organ systems and is characterized by chronic hemolysis, vaso-occlusion, and episodes of acute pain crises. Given the complex nature of both HIV and SCD, the use of ART must be carefully considered, as the drugs that are effective against HIV can sometimes exacerbate or complicate SCD-related pathophysiology. The toxicities of ART in SCD patients primarily affect hematologic, renal, hepatic, and bone health, which necessitates close monitoring and individualized care.²¹⁻²²

Hematologic

Toxicity

One of the most significant concerns when using ART in SCD patients is the risk of hematologic toxicity. SCD itself leads to chronic anemia due to the destruction of sickled red blood cells, and the need for blood transfusions is common. Some ART medications, particularly certain nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine and stavudine, are known to cause bone marrow suppression, which can exacerbate the anemia in SCD patients. This can lead to further reductions in red blood cell production, increased fatigue, and a greater risk of severe anemia. Additionally, these drugs can contribute to neutropenia and thrombocytopenia, which increase the likelihood of infections and bleeding events. In individuals with SCD, where blood cell production is already compromised due to the disease, these toxicities can pose serious challenges and necessitate adjustments in the ART regimen.²³⁻²⁴

Renal

Renal toxicity is another concern for individuals with both HIV and SCD. Sickle cell disease predisposes individuals to kidney dysfunction due to vaso-occlusive events and glomerulopathy, which can eventually lead to chronic kidney disease (CKD). ART medications, especially tenofovir disoproxil fumarate (TDF) and other NRTIs, have been linked to nephrotoxicity, which can further compromise renal function. The combination of SCD-related renal issues and ART-induced nephrotoxicity increases the risk of rapid progression to end-stage renal disease (ESRD), necessitating careful monitoring of renal function. Regular assessment of serum creatinine, glomerular filtration rate (GFR), and urine protein levels are essential for detecting early signs of renal impairment and adjusting ART regimens accordingly.²⁵⁻²⁶

Hepatic

Toxicity

The liver plays a crucial role in metabolizing many medications, and individuals with SCD may already have liver-related complications due to hemolysis, transfusions, and possible iron overload. ART drugs, particularly protease inhibitors (PIs) such as lopinavir/ritonavir and atazanavir, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz, have been associated with hepatic toxicity, including hepatomegaly, elevated liver enzymes, and, in severe cases, hepatic failure. Hepatotoxicity can be problematic in SCD patients, as the liver's ability to process and clear toxins is already under strain. Monitoring liver function through regular liver enzyme tests and adjusting ART medications when necessary is crucial to avoid further complications.²⁷⁻²⁸

Bone Health and Osteopenia

Osteopenia and osteoporosis are common complications in patients with SCD due to chronic hemolysis, low oxygen states, and

vitamin D deficiencies. Some ART drugs, especially tenofovir and other NRTIs, have been associated with bone mineral density (BMD) reduction, which can increase the risk of fractures and exacerbate existing bone health problems. In the context of SCD, this further increases the risk of skeletal deformities, pain crises, and fractures. Patients receiving ART should be monitored for BMD, and, when necessary, interventions such as calcium and vitamin D supplementation or the use of bisphosphonates may be considered to protect bone health.²⁹⁻³⁰

Drug-Drug

Interactions

In SCD patients, polypharmacy is common, as they often receive treatment for pain management, blood transfusions, and hydroxyurea. Additionally, the use of ART drugs in this population can lead to significant drug-drug interactions, which may either decrease the efficacy of the ART regimen or exacerbate SCD-related complications. For instance, certain ART medications may interact with hydroxyurea or other medications used to manage SCD, such as anticoagulants or pain-relieving drugs, altering their effectiveness or increasing the risk of adverse effects. A thorough review of the patient's medication regimen, coupled with routine monitoring for interactions, is essential for optimizing treatment outcomes and preventing harm.³¹⁻³²

Balancing ART and SCD Treatment

The treatment of individuals with both HIV and sickle cell disease (SCD) requires a delicate balance between managing the two conditions simultaneously, each of which presents distinct therapeutic challenges. Antiretroviral therapy (ART) is critical for controlling HIV and preventing disease progression, while SCD requires treatment aimed at preventing vaso-occlusive crises, reducing pain, managing anemia, and preventing complications

such as stroke or organ damage. The challenge in managing these comorbidities lies in the fact that the medications used for ART may exacerbate the complications of SCD, and vice versa. Therefore, an individualized approach to treatment that considers both the efficacy and toxicity of therapies is essential for optimizing patient outcomes.³³⁻³⁴

ART and SCD Symptom Management

Effective management of HIV in patients with SCD is contingent upon selecting the appropriate ART regimen that minimizes drug-related side effects. For instance, certain NRTIs, such as zidovudine, can cause bone marrow suppression, which can exacerbate the anemia already present in SCD patients. This necessitates the careful choice of ART drugs that do not interfere with red blood cell production. Additionally, protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) are commonly used but may interact with medications used to manage SCD symptoms, such as hydroxyurea, which can affect immune function, blood cell production, and renal health. Close monitoring of these interactions through regular blood tests and adjustments in treatment protocols is necessary to ensure that ART effectively suppresses HIV without worsening SCD-related complications.³⁵⁻³⁶

Pain Management Considerations

Managing pain in SCD patients is another area where balancing ART with SCD treatment is crucial. Pain crises are common in individuals with SCD, and opioid medications are often required to control this acute pain. However, opioid use in HIV-positive SCD patients can complicate treatment, especially when interacting with ART, which may alter drug metabolism or increase the risk of side effects like sedation or respiratory depression. Additionally, ART drugs themselves may contribute to chronic pain or neuropathy, adding another layer of

complexity to pain management. Integrating multidisciplinary care teams, including hematologists, infectious disease specialists, pain management experts, and pharmacists, is key to balancing these competing needs. Regular assessment of pain control, opioid use, and ART toxicity is necessary to ensure that both HIV and SCD symptoms are managed effectively without compromising patient safety.³⁷

Renal and Hepatic Function Monitoring

Another important aspect of balancing ART and SCD treatment is the monitoring of renal and hepatic function. Both conditions predispose individuals to kidney damage, with SCD contributing to chronic kidney disease and ART, particularly tenofovir, having nephrotoxic potential. Similarly, some ART medications may contribute to liver toxicity, which can complicate the management of SCD in patients with liver impairment. Regular monitoring of kidney and liver function is essential to ensure the safety of ART drugs in individuals with SCD. In cases where renal or hepatic dysfunction is noted, adjustments in ART regimens or dosage may be necessary, and the management of SCD-related complications such as iron overload, which can exacerbate organ damage, should also be addressed. Collaboration between nephrologists, hepatologists, and HIV specialists ensures that both organ systems are properly managed while minimizing treatment-related risks.³⁸

Individualized Treatment Strategies

Given the complexity of managing both HIV and SCD, individualized treatment strategies are essential. This includes tailoring ART regimens to the patient's specific needs, considering factors such as kidney function, bone health, and the potential for drug-drug interactions with SCD treatments. For example, the use of ART drugs like dolutegravir, an INSTI, may be preferred in certain patients as it is

associated with fewer side effects compared to other drugs. Similarly, alternative treatments for SCD, such as hydroxyurea or blood transfusions, may need to be adjusted based on the patient's HIV treatment regimen to avoid complications. Close monitoring of laboratory parameters, such as complete blood counts, liver and kidney function, and bone mineral density, should guide the management of both HIV and SCD.³⁹

Long-Term Management and Coordination of Care

Long-term management of individuals with both HIV and SCD requires ongoing care coordination between multidisciplinary teams. These teams must work together to monitor the patient's condition, adjust treatment regimens, and manage the myriad of potential complications associated with both conditions. Patient education is also a critical aspect of long-term management, ensuring that individuals understand the potential interactions between HIV medications and SCD treatments, as well as the importance of regular medical check-ups to monitor their overall health. An effective care plan requires not only careful pharmacological management but also a focus on lifestyle factors, such as hydration, nutrition, and exercise, which can improve the overall well-being of individuals with both conditions.⁴⁰

Strategies for Optimizing Antiretroviral Therapy in Sickle Cell Disease

Optimizing antiretroviral therapy (ART) in individuals with sickle cell disease (SCD) requires a multifaceted approach that balances the efficacy of HIV treatment with the unique challenges posed by the pathophysiology of SCD. Given the complex interactions between ART medications and the underlying hematologic and immunologic disturbances of SCD, individualized

management strategies are crucial to achieve optimal clinical outcomes. The goal is to maintain effective HIV suppression while minimizing treatment-related toxicities, particularly those that may exacerbate SCD-related complications such as anemia, pain crises, organ dysfunction, and immune dysregulation. The following strategies outline key considerations for optimizing ART in patients with SCD.⁴¹

1. Careful Selection of ART Regimens

The first step in optimizing ART in SCD patients is the careful selection of drugs that are effective against HIV but have minimal adverse effects on blood cell production and other SCD-related complications. Nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine, may exacerbate anemia and bone marrow suppression, which are common in individuals with SCD. Therefore, alternatives like tenofovir or lamivudine are preferred, as they are less likely to interfere with red blood cell production. Additionally, the choice of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) should be guided by their potential interactions with other medications used to manage SCD, such as hydroxyurea, and their risk for hepatotoxicity. Integrase strand transfer inhibitors (INSTIs), like dolutegravir, are increasingly being considered for use in SCD patients due to their favorable side effect profiles and low potential for drug interactions.⁴²⁻⁴³

2. Monitoring for ART Toxicities

Given the increased risk of drug toxicities in individuals with both HIV and SCD, regular monitoring is essential to detect adverse effects early. Some ART drugs, particularly PIs and tenofovir, can lead to nephrotoxicity, which may compound the kidney dysfunction seen in SCD patients. Monitoring renal function through serum creatinine levels, glomerular filtration rate

(GFR), and urine protein-to-creatinine ratio is critical. Additionally, ART regimens can affect bone mineral density, which is already compromised in individuals with SCD due to factors like chronic hemolysis and repeated blood transfusions. Regular screening for osteoporosis and adjusting ART medications, such as considering alternative NRTIs or INSTIs, may help prevent further bone loss. Liver function should also be monitored closely, as ART drugs can contribute to hepatic toxicity, which may exacerbate the hepatic complications of SCD, such as iron overload.⁴⁴

3. Managing Drug-Drug Interactions

Another key strategy in optimizing ART for SCD patients is managing drug-drug interactions. Medications used to manage SCD, such as hydroxyurea, are known to interact with certain ART drugs, particularly PIs and some NNRTIs. Hydroxyurea, which is commonly used to reduce pain crises and prevent stroke in children with SCD, can affect the immune system and bone marrow, and its interaction with ART can alter drug metabolism or increase side effects. Therefore, close monitoring of hematologic parameters, such as white blood cell count and platelet levels, is essential when combining ART with hydroxyurea. When selecting ART for individuals with SCD, it is important to choose drugs that do not interfere with the pharmacokinetics of SCD treatments, ensuring that both HIV and SCD are effectively managed. In some cases, dose adjustments or the use of alternative medications may be necessary to avoid harmful interactions.⁴⁵

4. Addressing Co-Morbidities

Patients with both HIV and SCD often experience additional co-morbidities, such as chronic pain, cardiovascular disease, and respiratory complications, which can complicate ART management. Chronic pain associated with SCD, particularly

vaso-occlusive crises, may require the use of opioids or other analgesics, which can interact with ART medications and affect patient safety. The use of ART medications that do not further complicate pain management is important, and non-opioid analgesics or adjuvant therapies like gabapentin may be considered when possible. Furthermore, cardiovascular and pulmonary complications in SCD patients, such as pulmonary hypertension and stroke, may also be influenced by ART medications. Regular screening for these complications and coordinating care with specialists, such as cardiologists or pulmonologists, is essential to optimize the overall management of both conditions.⁴⁶

5. Multidisciplinary Care and Patient Education

The management of HIV in SCD patients requires a multidisciplinary approach that includes hematologists, infectious disease specialists, pharmacists, and pain management experts. Collaborative care ensures that all aspects of the patient's health are addressed, and treatment decisions are made with consideration of the full spectrum of disease interactions. Patient education is also critical in ensuring adherence to both ART and SCD treatments. Patients must understand the importance of adhering to their HIV regimen while managing SCD-related symptoms and avoiding treatment-related complications. Providing education on potential drug interactions, the importance of routine monitoring, and self-management strategies for pain and other SCD symptoms can improve outcomes and quality of life.⁴⁷⁻⁴⁸

Conclusion

Managing HIV in patients with sickle cell disease (SCD) requires a nuanced and individualized approach, balancing the efficacy of antiretroviral therapy (ART) with the potential toxicities that may exacerbate SCD complications. Careful

selection of ART medications, regular monitoring for side effects, and addressing drug interactions are essential components of an effective treatment plan. In addition, managing the co-morbidities associated with both HIV and SCD, including chronic pain, cardiovascular issues, and organ dysfunction, is crucial for optimizing patient outcomes. A multidisciplinary care team, including hematologists, infectious disease specialists, pharmacists, and other healthcare providers, ensures that all aspects of the patient's health are addressed. Furthermore, patient education plays a vital role in promoting adherence and managing the complex treatment regimens. By prioritizing individualized care plans and optimizing ART regimens, healthcare providers can significantly improve the quality of life and health outcomes for HIV-positive individuals with sickle cell disease. Ongoing research into the pharmacodynamics and interactions of ART medications with SCD treatments will continue to inform clinical practices and enhance the management of this unique patient population. Ultimately, a comprehensive and holistic approach is key to achieving the best possible outcomes for these patients, ensuring that both HIV and SCD are effectively managed without exacerbating one another.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. *Clinical Infectious Diseases*. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. *Transfusion Medicine Reviews*. 2019; 33(3):162-169.

3. Ola B, Olushola O, Ebenso B, Berghs M. Sickie Cell Disease and Its Psychosocial Burdens in Africa. In Sickie Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickie cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickie cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: [http://www.journalijar.com](http://www.journalijar.com;);12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: <http://ajdhs.com/index.php/journal/article/view/62>
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. <http://hdl.handle.net/20.500.12493/14626>
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in

- HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
 23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
 24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficiency virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
 25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
 26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
 27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
 28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
 29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
 30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
 31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
 32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
 33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
 34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
 35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
 36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
 37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
 38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-

- sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
 40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre- and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
 41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
 42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
 43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
 44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
 45. Ashenafi G, Tibebe M, Tilahun D, Tsegaye A. Immuno-hematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
 46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
 47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
 48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40